MetaCap

Tandem Diabetes Care Inc. (TNDM)

NASDAQ: TNDMHealth CareMedical/Dental InstrumentsUSD

17.46+0.66 (+3.93%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TNDM stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.70
52-week range
12.26 – 29.65
Day range
16.51 – 17.86
Volume / Avg
2.67M / 2.26M
Beta
—

52-week range

$12.26$29.65

TNDM stock today

Shares of Tandem Diabetes Care (TNDM) finished higher on Nov 20 at $17.46, a gain of 3.93% or $0.66 per share, versus the S&P 500's 3.70% decline. Shares are 41.1% below their 52-week high of $29.65, set on Feb 24, 2026 and 42.4% above the 52-week low of $12.26, in the middle of the past year's range. TNDM is down 20.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 18.0%.

Tandem Diabetes Care has posted a net loss over the last twelve months (EPS of -$0.70), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Tandem Diabetes Care

Company profile

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system.

Industry
Medical/Dental Instruments
CEO
Mr. John F. Sheridan
Headquarters
San Diego, CA
Employees
2,500
IPO year
2013

Financial highlights

Full financials

In fiscal 2025, Tandem Diabetes Care generated $1.01 billion in revenue, up 7.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Tandem Diabetes Care reported a net loss of $204.7 million, compared with a loss of $96.0 million a year earlier. Gross margin was 53.8% (up from 52.1%) and operating margin -18.5%.

Tandem Diabetes Care annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.01B$940.20M$747.72M$801.22M$702.80M
Growth+7.93%+25.74%-6.68%+14.00%+40.89%
Net income$-204.71M$-96.03M$-222.61M$-94.59M$15.57M
EPS (diluted)$-3.04$-1.47$-3.43$-1.47$0.24

Analyst forecast

Forecast

Consensus (25 analysts)

buy

Avg. price target

$27.10+55.21%

  • Strong buy 2
  • Buy 12
  • Hold 11
  • Sell 0
  • Strong sell 0

Target range

Low $18.00High $50.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.10 vs $-0.27
Surprise
+62.96%

TNDM news

All TNDM news

Tandem Diabetes Care peers

Health Care sector
TNDM peer companies
CompanyPrice% ChgMarket capCompare
NVCRNovoCure Limited10.71+0.19%$1.25Bvs TNDM
DRTSAlpha Tau Medical Ltd.11.76+3.93%$1.09Bvs TNDM
SIBNSI-BONE Inc.23.73-0.08%$1.07Bvs TNDM
IRMDiRadimed Corporation81.02-0.30%$1.04Bvs TNDM
IARTIntegra LifeSciences Holdings Corporation13.25-2.21%$1.03Bvs TNDM
ATECAlphatec Holdings Inc.6.68-3.19%$1.02Bvs TNDM
SGPSpyGlass Pharma Inc.30.43-1.14%$1.02Bvs TNDM
PRCTPROCEPT BioRobotics Corporation24.70-4.08%$1.42Bvs TNDM

Indexes, lists and sector

Tandem Diabetes Care stock FAQ

What is Tandem Diabetes Care's stock price today?

TNDM last traded at $17.46 as of Nov 20, 4:00 PM EST, up 3.93% on the day. Prices are delayed at least 15 minutes.

Does Tandem Diabetes Care pay a dividend?

No. Tandem Diabetes Care does not currently pay a regular cash dividend.

Who is Tandem Diabetes Care's CEO?

Mr. John F. Sheridan is the chief executive officer of Tandem Diabetes Care Inc., which has about 2,500 employees.

Has TNDM ever split its stock?

Yes. The most recent TNDM stock split was a 1-for-10 split on Oct 10, 2017.

What is the TNDM 52-week high?

The 52-week high for TNDM is $29.65 and the 52-week low is $12.26. The stock is currently 41.1% below its high.

Compare TNDM